Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Annovis Bio, Inc. (ANVS : NYSE)
 
 • Company Description   
Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

Number of Employees: 8

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.53 Daily Weekly Monthly
20 Day Moving Average: 454,986 shares
Shares Outstanding: 14.24 (millions)
Market Capitalization: $21.78 (millions)
Beta: 1.46
52 Week High: $17.88
52 Week Low: $1.11
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 17.69% 11.53%
12 Week -43.96% -39.45%
Year To Date -69.58% -68.39%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
101 Lindenwood Drive Suite 225
-
Malvern,PA 19355
USA
ph: 484-875-3192
fax: -
nic.johnson@russopartnersllc.com http://www.annovisbio.com
 
 • General Corporate Information   
Officers
Maria Maccecchini - Chief Executive Officer and President
Michael Hoffman - Chairman of the Board and Director
Claudine Bruck - Director
Reid McCarthy - Director
Mark White - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03615A108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 05/12/25
Share - Related Items
Shares Outstanding: 14.24
Most Recent Split Date: (:1)
Beta: 1.46
Market Capitalization: $21.78 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.49 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.68 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.27
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 60.55%
vs. Previous Quarter: 55.67%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/25 - -
12/31/24 - -872.99
09/30/24 - -
ROA
03/31/25 - -
12/31/24 - -239.04
09/30/24 - -311.00
Current Ratio
03/31/25 - -
12/31/24 - 3.59
09/30/24 - 2.66
Quick Ratio
03/31/25 - -
12/31/24 - 3.59
09/30/24 - 2.66
Operating Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Net Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Pre-Tax Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Book Value
03/31/25 - -
12/31/24 - 0.67
09/30/24 - 0.54
Inventory Turnover
03/31/25 - -
12/31/24 - -
09/30/24 - -
Debt-to-Equity
03/31/25 - -
12/31/24 - 0.00
09/30/24 - 0.00
Debt-to-Capital
03/31/25 - -
12/31/24 - 0.00
09/30/24 - 0.00
 

Powered by Zacks Investment Research ©